Category

South Korea

Daily Brief South Korea: Shinhan Financial, Hana Tour Service, Hanmi Science, WCP and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Shinhan Financial Group Placement – Another Selldown, Momentum Is Strong but Deal Is Large
  • Block Deal Sale of 3.6% Stake in Shinhan Financial by BNP Paribas
  • HanaTour Management Sale: Minority Shareholder Tender Offer & Price Premium Assessment
  • Hanmi Science: NPS Sides With Mother (Chairwoman) And Daughter
  • Hana Tour Service: Major Shareholders Including IMM PE Likely to Sell Their Shares
  • W-Scope IPO Lock-Up – Part of the Parent’s Stake Will Be Freed, but It’s Been Adding Instead


Shinhan Financial Group Placement – Another Selldown, Momentum Is Strong but Deal Is Large

By Sumeet Singh

  • BNP Paribas (BNP FP) is looking to raise around US$680m via selling 3.5% of its stake in Shinhan Financial (055550 KS).
  • This will be the fourth selldown for the stock since the start of the year. It will also be the largest one of the lot, so far.
  • In this note, we will talk about the deal dynamics and run the deal through our ECM framework.

Block Deal Sale of 3.6% Stake in Shinhan Financial by BNP Paribas

By Douglas Kim

  • After the market close on 26 March, it was announced that BNP Paribas plans to sell its 3.6% stake in Shinhan Financial in a block deal sale 18.7 million shares). 
  • The block deal sale is estimated to be about 900 billion won, which would represent one of the largest block deal sales in Korea in the past several years.
  • We have a Negative view on the Shinhan Financial Group block deal and we would not subscribe to it due to three major reasons. 

HanaTour Management Sale: Minority Shareholder Tender Offer & Price Premium Assessment

By Sanghyun Park

  • HanaTour seeks new ownership after 4 years under IMM PE. Despite COVID-19 setbacks, successful restructuring attracts attention from online travel and investment giants.
  • Market rumors hint at Yanolja and Hotels.com interest, possibly intensifying acquisition competition, leading to a higher price premium. IMM’s 16.68% stake may value at ₩250B, a 35% premium.
  • Last year’s mandatory tender offer for 50%+1 share awaits legislation. Unlikely to affect HanaTour sale. Nonetheless, potential acquirers may buy additional shares, suggesting further premium formation in share price.

Hanmi Science: NPS Sides With Mother (Chairwoman) And Daughter

By Douglas Kim

  • After the market close on 26 March, it was reported that NPS has decided it will side with Chairwoman Young-Sook Song (mother) and her daughter Ju-Hyun Lim. 
  • As a result, Chairwoman Young-Sook Song (mother) and Ju-Hyun Lim have secured 40.86% of the shares, which is slightly higher than the ownership of her two sons (38.4%). 
  • In the near term, this battle for the control of the company could have a positive impact on Hanmi Science’s share price. 

Hana Tour Service: Major Shareholders Including IMM PE Likely to Sell Their Shares

By Douglas Kim

  • Hana Tour Service (039130 KS), the number one travel platform in Korea,  announced that IMM PE (controlling shareholder of the company) is planning to sell its controlling stake. 
  • The total stake in the company that is up for sale could rise to 27.78%, including stakes held by Hana Tour founder Park Sang-hwan and co-founder Kwon Hee-seok. 
  • Potential buyers of the controlling stake in Hana Tour include Yanolja, Hotels.com, Booking.com, and Trip.com.

W-Scope IPO Lock-Up – Part of the Parent’s Stake Will Be Freed, but It’s Been Adding Instead

By Sumeet Singh

  • WCP raised around US$314m via selling a mix of primary and secondary shares in its Korean IPO. The lockup on some of its parent’s stake will expire soon.
  • WCP designs, manufactures, and sells separators, which are one of the four core materials for secondary Lithium-ion batteries.
  • In this note, we will talk about the lock-up dynamics and updates since our last note.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: HD Hyundai , SillaJen Inc and more

By | Daily Briefs, South Korea

In today’s briefing:

  • HD Hyundai Marine Solution IPO Preview
  • SillaJen Rights Offering Worth 34% of Outstanding Shares


HD Hyundai Marine Solution IPO Preview

By Douglas Kim

  • HD Hyundai Marine Solution is getting ready to complete its IPO in KOSPI in May 2024. This will be one of the largest IPOs in Korea in 2024. 
  • The IPO price range is from 73,300 won to 83,400 won. The IPO offering amount is from 652.4 billion won to 742.3 billion won. 
  • A key beneficiary of HD Hyundai Marine Solution IPO is HD Hyundai (62% ownership). Our NAV analysis suggests implied price of 95,632 for HD Hyundai (40% higher than current price).

SillaJen Rights Offering Worth 34% of Outstanding Shares

By Douglas Kim

  • On 22 March, SillaJen Inc (215600 KS) announced that it will conduct a rights offering worth about 129 billion won for R&D and financials improvement.  
  • The rights offering size is 34.5 million shares, representing 34% of total outstanding shares. The expected rights offering price is 3,750 won which is 26% lower than current price. 
  • We would not subscribe to this rights offering and we remain negative on the company.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: HLB Life Science, C&C International Corp and more

By | Daily Briefs, South Korea

In today’s briefing:

  • HLB Life Science: Impact of Rights Offering Capital Raise of 150 Billion Won
  • Special Changes in KOSDAQ 150: Deletion (CanariaBio) + Addition  (C&C International)


HLB Life Science: Impact of Rights Offering Capital Raise of 150 Billion Won

By Douglas Kim

  • On 21 March, HLB Life Science announced a rights offering capital raise worth 150 billion won. 
  • The expected rights offering price is 13,630 won (32% lower than current price of 19,930 won)  and there are 11 million shares in this rights offering (10% of outstanding shares). 
  • HLB Inc (028300 KS) is the largest controlling shareholder of HLB Life Science (067630 KS) with an 18.7% stake in the company.

Special Changes in KOSDAQ 150: Deletion (CanariaBio) + Addition  (C&C International)

By Douglas Kim

  • On 22 March, the Korea Exchange announced special changes to KOSDAQ 150. CanariaBio will be excluded from KOSDAQ 150 and it will be replaced by C&C International.
  • Canaria Bio was designated as “administrative issue” and “investment attention issue” on 22 March 2024, which resulted in KRX deciding to remove this stock from KOSDAQ 150 on 26 March.
  • We believe that this inclusion of C&C International in KOSDAQ 150 is likely to further positively impact its share price.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: PSK Holdings Inc, Daishin Securities and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Special Changes in KOSDAQ 150: Deletion – STCube (052020) And Addition – PSK Holdings (031980)
  • Daishin Securities: Announces A Capital Raise of 230 Billion Won Through RCPS


Special Changes in KOSDAQ 150: Deletion – STCube (052020) And Addition – PSK Holdings (031980)

By Douglas Kim

  • KRX announced special changes to KOSDAQ 150. Since STCube (052020 KS) has been designated as “administrative issue,” the Korea Exchange will exclude it from KOSDAQ 150 on 26 March 2024. 
  • PSK Holdings Inc (031980 KS) will be new addition to KOSDAQ 150 index, replacing ST Cube.
  • PSK Holdings’ core business is providing process technology, source, and hardware for semiconductor packaging equipment.

Daishin Securities: Announces A Capital Raise of 230 Billion Won Through RCPS

By Douglas Kim

  • After the market close on 21 March, Daishin Securities announced a capital raise worth 230 billion won through RCPS. Daishin Securities currently has a market cap of 901 billion won. 
  • Through this issue of 230 billion won in RCPS, Daishin Securities achieved 3 trillion won in equity capital, which is a condition for applying as a comprehensive financial investment business.
  • We are Negative on Daishin Securities in the next 6-12 months as the concerns about RCPS capital raise related shares dilution are likely to weigh negatively on its stock price.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: Doosan Robotics , Samsung Card Co, Jeil Machine & Solution and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Quiddity Leaderboard KOSPI 200 Jun 24: Up to Five Changes Possible
  • Noteworthy Price Movements Associated with 1Q Ex-Dates Trading Setups
  • Jeil Machine & Solution IPO Valuation Analysis


Quiddity Leaderboard KOSPI 200 Jun 24: Up to Five Changes Possible

By Travis Lundy

  • KOSPI 200 is a Korean blue-chip index that tracks the 200 largest and most-liquid names listed in the KOSPI section of the Korea Exchange (KRX).
  • In this insight, we take a look at the names leading the race to become ADDs and DELs during the upcoming semiannual review in June 2024.
  • There could be up to five changes in the KOSPI 200 index during the June 2024 index rebal event.

Noteworthy Price Movements Associated with 1Q Ex-Dates Trading Setups

By Sanghyun Park

  • Investors buying on February ex-dates, perhaps due to the Value-up factor, led to a successful strategy for local managers: buying before ex-date and selling at close, yielding positive results.
  • On March 19th, Kia Corp (000270 KS) diverged from February’s pattern. Notably, FINANCIAL INVESTMENT sold heavily on Kia’s ex-date, a deviation from their quiet February activity.
  • FINANCIAL INVESTMENT’s trend of liquidating positions held since last quarter, especially for dividends, gains momentum as March ends, possibly overshadowing February’s Value-up factor.

Jeil Machine & Solution IPO Valuation Analysis

By Douglas Kim

  • Our base case valuation of Jeil M&S is target price of 24,354 won per share, which is 35% higher than the high end of the IPO price range.
  • We estimate the Jeil M&S to generate sales of 279 billion won (up 94.9% YoY) and operating profit of 18.1 billion won (up 928% YoY).
  • Jeil M&S’s main products include mixing equipment for the rechargeable battery sector. Its major customers include Samsung SDI, LG Energy Solution, and Northvolt. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: Jeil Machine & Solution, Korea Stock Exchange KOSPI 200 and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Jeil Machine & Solution IPO Preview
  • EQD | KOSPI 200 WEEKLY Bottom May Be Behind the Corner


Jeil Machine & Solution IPO Preview

By Douglas Kim

  • Jeil Machine & Solution is getting ready for an IPO in April in the Korean stock market. The IPO price range is 15,000 won to 18,000 won. 
  • The total offering amount ranges from 36 billion won to 43.2 billion won. The book building for the institutional investors will last from 5 to 12 April. 
  • According to the bankers’ assessment, the implied market cap of the company ranges from 309 billion won to 371 billion won. 

EQD | KOSPI 200 WEEKLY Bottom May Be Behind the Corner

By Nico Rosti

  • The KOSPI 200 INDEX is falling for the second week in a row, but the pullback is modest so far.
  • This pullback is probably just another occasion to buy at better prices, however some more pullback may be in store between here and the end of the week.
  • The support area where we think a LONG trade has good probability of success based on our models is between 356 and 350.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: LG Corp, Samsung C&T, Wins Co Ltd and more

By | Daily Briefs, South Korea

In today’s briefing:

  • LG Corp: Updated NAV Analysis Amid Ongoing Corporate Value Up Program in Korea
  • Exploring Trading Setups Utilizing NPS’s ESG Fund Flows After July
  • Korea Small Cap Gem #27: Wins Co.


LG Corp: Updated NAV Analysis Amid Ongoing Corporate Value Up Program in Korea

By Douglas Kim

  • Our NAV analysis of LG Corp suggests an implied market cap of 16.3 trillion won or 103,781 won per share which is 16% higher than current share price.
  • For holdco discount, we used a 50% holdco discount. If investors perceive improvement in value (such as through corporate governance improvements), the holdco discount on LG Corp would decline.
  • LG Corp’s shares are up 5.9% in the past six months, outperforming all the major LG Group related companies including LG Chem, LG H&H, LG Electronics, and LG Energy Solution. 

Exploring Trading Setups Utilizing NPS’s ESG Fund Flows After July

By Sanghyun Park

  • From July, Korea’s listed firms will disclose value enhancement plans. Korea’s NPS may exclude non-compliant firms, pending official response, though internal review suggests likely implementation.
  • It’s crucial to know portfolio stocks for proactive positioning. A setup targeting potential exclusion from NPS’s ESG funds due to post-July compliance must be designed.
  • Managers often use KRX ESG Leaders 150, aligning portfolios with it. Thus, it’s crucial to use this list for post-July compliance monitoring and to adapt setups for NPS’s flow impacts.

Korea Small Cap Gem #27: Wins Co.

By Douglas Kim

  • Wins Co. is engaged in the business of developing and supplying information security solutions and developing software related to network security to protect networks from cyber threats and viruses. 
  • The company has a consistent growth in sales and profits. It also has a strong balance sheet. At the end of 2023, it had a debt ratio of 15.4%. 
  • Wins Co is trading at EV/EBITDA of 1.7x, P/E of 7.8x, and P/B of 0.9x in 2024 which are 75%, 26%, and 25% lower than the historical valuation multiples.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: Korea Stock Exchange Kospi Index and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Investigating the Size and Timing of Korea’s Local Dividend Arbitrage Traders’ Position Liquidation


Investigating the Size and Timing of Korea’s Local Dividend Arbitrage Traders’ Position Liquidation

By Sanghyun Park

  • Estimating FINANCIAL INVESTMENT’s dividend arbitrage positions’ exact size and liquidation plans is challenging. Yet, past trading patterns suggest a substantial portion may be liquidated soon, akin to January’s volume (≥₩2T).
  • Many local market participants expect a scenario unfolding post-March, aligning with KOSPI companies rescheduling ex-dividend dates. Expect substantial position liquidation by April’s end, likely impacting index negatively, akin to January.
  • Position setups should adapt to short-term index corrections, leveraging earnings season for earnings-based spreads using index short hedging.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: Hanjin KAL Corp and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Another Brewing Fight for the Controlling Shareholding of Hanjin Kal?


Another Brewing Fight for the Controlling Shareholding of Hanjin Kal?

By Douglas Kim

  • On 14 March, NPS announced that it has decided to vote against the re-appointment of the CEO Cho Won-tae as the executive director of Korean Air Lines.
  • It was also announced on 14 March that GS Retail purchased a 1% stake in Hanjin Kal. In addition, Korean Air Lines also purchased a 1.2% stake in GS Retail.
  • One of the growing probabilities of the changing shareholding structures is that KDB may be interested in selling its 10.6% stake in Hanjin Kal.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: Korea Stock Exchange Kospi Index, Angel Robotics , Dongwon Industries, Hanmi Pharm and more

By | Daily Briefs, South Korea

In today’s briefing:

  • New Information on Korea Value-Up Index Scoring System & Constituent Weighting
  • Angel Robotics: IPO Bookbuilding Results Analysis
  • An Update of the Potential KOSPI200 Rebalance Candidates in June 2024
  • OCI Or No OCI, Hanmi Pharm (128940 KS) Will Continue to Roar on Strong Base Business and Pipeline


New Information on Korea Value-Up Index Scoring System & Constituent Weighting

By Sanghyun Park

  • KRX considers a comprehensive change to the Value-up Index scoring system. Weightings emphasize ROE, PER, and FCF while reducing PBR weight.
  • KRX considers adopting scoring-based constituent weighting to prevent JPX Prime 150’s issues, but NPS opposes. Float market cap weighting like JPX Prime 150 is contemplated to address concerns.
  • Momentum trading in the Value-up initiative will favor low PER and high ROE stocks over low PBR. The semiconductor sector is anticipated to benefit significantly from float market cap-based weighting.

Angel Robotics: IPO Bookbuilding Results Analysis

By Douglas Kim

  • Angel Robotics reported exceptional IPO bookbuilding results. Angel Robotics’ IPO price has been determined at 20,000 won, which is 33% higher than the high end of the IPO price range. 
  • A total of 2,067 institutional investors participated in this IPO book building. The demand ratio was 1,157 to 1. Angel Robotics will start trading on 26 March 2024. 
  • We remain positive on Angel Robotics. There is likely to be a sharp overshooting of its share price relative to its intrinsic value on the first day of trading. 

An Update of the Potential KOSPI200 Rebalance Candidates in June 2024

By Douglas Kim

  • We provide an update of the potential KOSPI200 rebalance candidates in June 2024. 
  • The bottom 5% market caps in KOSPI200 could be excluded from the KOSPI200 rebalance in June 2024. These 10 stocks are down on average 12.6% YTD. 
  • We identified seven potential inclusion candidates. Among them, those that have low PBR multiples including HHI and Dongwon Industries could continue to outperform the market leading up to rebalance announcement. 

OCI Or No OCI, Hanmi Pharm (128940 KS) Will Continue to Roar on Strong Base Business and Pipeline

By Tina Banerjee

  • In 2023, Hanmi Pharm (128940 KS) reported 12% and 40% growth in revenue and operating profit, respectively, driven by double-digit revenue increase from Rosuzet and improving performance of China subsidiary.
  • In January, the company has enrolled first patient in phase 3 trial of type 2 diabetes/obesity drug candidate Efpeglenatide. The study is expected to complete in 2026.
  • Hanmi Science-OCI merger has hit a roadblock. Although merger with OCI will bring synergistic effect, Hanmi Pharm will continue to grow even if the merger does not happen.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars